Evolus, Inc. (NASDAQ:EOLS) Holdings Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 421,481 shares of the company’s stock after purchasing an additional 2,905 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.67% of Evolus worth $4,653,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. KBC Group NV bought a new position in Evolus during the 4th quarter worth $49,000. IFP Advisors Inc boosted its holdings in shares of Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after acquiring an additional 4,709 shares during the period. Point72 Asset Management L.P. bought a new position in shares of Evolus during the third quarter worth about $132,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Evolus in the 3rd quarter worth about $191,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Evolus by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock valued at $148,000 after purchasing an additional 1,291 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have commented on EOLS shares. HC Wainwright restated a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Wednesday, March 5th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Wednesday, March 5th. Finally, Barclays raised their target price on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th.

Insider Activity at Evolus

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $60,147.36. Following the completion of the sale, the chief marketing officer now directly owns 95,671 shares of the company’s stock, valued at approximately $1,268,597.46. This represents a 4.53 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rui Avelar sold 27,904 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the transaction, the insider now owns 362,467 shares of the company’s stock, valued at approximately $4,806,312.42. This trade represents a 7.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,324 shares of company stock worth $716,856 over the last quarter. 6.10% of the stock is currently owned by company insiders.

Evolus Stock Down 4.4 %

EOLS stock opened at $12.43 on Wednesday. The firm’s 50-day moving average is $13.55 and its two-hundred day moving average is $13.84. The company has a market capitalization of $790.39 million, a price-to-earnings ratio of -13.66 and a beta of 1.28. Evolus, Inc. has a 52 week low of $9.25 and a 52 week high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.